[HTML][HTML] Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Y Xu, H Ye - Experimental Hematology & Oncology, 2022 - Springer
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Y Xu, H Ye - Experimental Hematology & Oncology, 2022 - search.proquest.com
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors.
Y Xu, H Ye - Experimental Hematology & Oncology, 2022 - europepmc.org
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
[HTML][HTML] Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Y Xu, H Ye - Experimental Hematology & Oncology, 2022 - ehoonline.biomedcentral.com
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
[HTML][HTML] Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Y Xu, H Ye - Experimental Hematology & Oncology, 2022 - ncbi.nlm.nih.gov
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Y Xu, H Ye - Experimental Hematology & Oncology, 2022 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Venetoclax is a new type of BH3 mimetic
compound that can target the binding site in the BCL-2 protein and induce apoptosis in …
compound that can target the binding site in the BCL-2 protein and induce apoptosis in …
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Y Xu, H Ye - Experimental hematology & oncology, 2022 - pubmed.ncbi.nlm.nih.gov
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
[PDF][PDF] Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Y Xu, H Ye - 2022 - ehoonline.biomedcentral.com
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …